Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00

Structure Therapeutics (NASDAQ:GPCR) had its price target boosted by Citizens Jmp from $87.00 to $120.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a market outperform rating on the stock.

Several other equities analysts have also commented on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Zacks Research lowered shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Stifel Nicolaus upped their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Friday. Finally, Lifesci Capital raised shares of Structure Therapeutics to a “strong-buy” rating in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.78.

Structure Therapeutics Stock Performance

GPCR opened at $67.06 on Friday. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $94.90. The business’s 50-day simple moving average is $35.52 and its 200 day simple moving average is $25.83. The firm has a market capitalization of $4.07 billion, a PE ratio of -54.97 and a beta of -1.64.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its position in shares of Structure Therapeutics by 9.4% in the third quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after purchasing an additional 413 shares during the period. Assetmark Inc. boosted its holdings in Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after buying an additional 820 shares during the period. EverSource Wealth Advisors LLC grew its stake in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after acquiring an additional 1,146 shares during the period. Finally, State of Wyoming bought a new stake in Structure Therapeutics during the 2nd quarter valued at $28,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.